STOCK TITAN

Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Acumen Pharmaceuticals to present at H.C. Wainwright conference
Positive
  • Positive: Acumen Pharmaceuticals presenting at H.C. Wainwright conference
Negative
  • None.

CHARLOTTESVILLE, Va. and CARMEL, Ind., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will present at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, Sept. 13, 2023 at 10:30 a.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

About Acumen Pharmaceuticals, Inc.

Acumen, headquartered in Charlottesville, VA, with clinical operations based in Carmel, IN, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble AβOs, following positive topline results in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com.

Investors:
Alex Braun
abraun@acumenpharm.com 

Media: 
AcumenPR@westwicke.com 


Acumen Pharmaceuticals, Inc.

NASDAQ:ABOS

ABOS Rankings

ABOS Latest News

ABOS Stock Data

177.24M
60.08M
11.24%
78.42%
2.11%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CHARLOTTESVILLE